M. D. Anderson Cancer Center SPORE in Multiple Myeloma

多发性骨髓瘤是一种克隆性浆细胞恶性肿瘤，尽管最近的治疗取得了进展，但在美国超过59,000名患有这种疾病的患者中，绝大多数人仍然无法治愈。因此，德克萨斯大学安德森癌症中心与宾夕法尼亚大学和弗吉尼亚联邦大学合作，提出了这一针对多发性骨髓瘤的卓越研究(孢子)专业计划。该计划的主要目标将是将有希望的新策略从替补席转化为床边，以降低发病率和死亡率，并提高多发性骨髓瘤患者的生活质量。为此，一个由经验丰富的调查人员组成的多学科协作小组将开展四个极具创新性的项目： 项目1-骨髓瘤的联合激活T细胞和疫苗治疗(夸克/吉拉特/六月/斯塔特毛尔) 项目2-抗(32-微球蛋白抗体)作为多发性骨髓瘤的治疗剂(YI/WANG)项目3-靶向多发性骨髓瘤的HDM-2 E3连接酶(Orlowski/Weber) 项目4-通过联合使用CDK抑制剂和Bcl-2拮抗剂来靶向多发性骨髓瘤(Grant/Wang/Dai/Dent) 为了提供项目取得最大成功所需的专门知识，这些项目将得到五个核心设施的支持： 核心A--行政核心基金(奥洛夫斯基/夸克) 核心B-骨髓瘤组织核心设施(Kornblau/Wang/Davis/Lin) 核心C-动物模型核心设施(易/杨) 核心D-临床试验核心设施(韦伯/斯塔特毛尔/麦克劳克林) 核心电子生物统计和生物信息学核心设施(Berry/Baladandayuthapani/Almeida/Ramakrishnan) 此外，该孢子将通过以下计划吸引新的具有新想法的研究人员，并培训下一代骨髓瘤研究人员： 发展研究计划(Orlowski A‘i) 职业发展计划(Kwak/Aggarwal/Stadtmauer) 因此，这一孢子将成为其研究人员和骨髓瘤研究界的纽带，促进必要的多学科努力，使我们更接近治愈这种疾病。

Multiple myeloma is a clonal plasma cell malignancy which, despite recent treatment advances, remains incurable in the vast majority of the over 59,000 patients in the United States afflicted with this disease. Therefore, The University of Texas M. D. Anderson Cancer Center, in collaboration with The University of Pennsylvania and the Virginia Commonwealth University, is proposing this Specialized Program of Research Excellence (SPORE) in Multiple Myeloma. The primary goal of this program will be to translate promising new strategies from the bench to the bedside to reduce the morbidity and mortality, and improve the quality of life of multiple myeloma patients. To do so, a multidisciplinary, collaborative group of experienced investigators will be pursuing four highly innovative Projects: Project 1 - Combination Activated T-Cell and Vaccine Therapy in Myeloma (Kwak/Giralt/June/Stadtmauer) Project 2 - Anti-(32-microglobulin Antibodies as Therapeutic Agents for Multiple Myeloma (Yi/Wang) Project 3-Targeting the HDM-2 E3 Ligase in Multiple Myeloma (Orlowski/Weber) Project 4 - Targeting Multiple Myeloma by Combining CDK Inhibitors and Bcl-2 Antagonists (Grant/Wang/Dai/Dent) To provide the specialized expertise needed to maximize the success of the Projects, they will be supported by five Core Facilities: Core A - Administrative Core Facility (Orlowski/Kwak) Core B - Myeloma Tissue Core Facility (Kornblau/Wang/Davis/Lin) Core C - Animal Models Core Facility (Yi/Yang) Core D - Clinical Trials Core Facility (Weber/Stadtmauer/McLaughlin) Core E - Biostatistics and Bioinformatics Core Facility (Berry/Baladandayuthapani/Almeida/ Ramakrishnan) Also, the SPORE will attract new investigators with additional novel ideas, and train the next generation of myeloma researchers, through the following Programs: Developmental Research Program (OrlowskiA'i) Career Development Program (Kwak/Aggarwal/Stadtmauer) This SPORE will therefore serve as a nexus for its Investigators and the myeloma research community to foster the kind of multidisciplinary efforts that are necessary to bring us closer to a cure for this disease.